$6.21 -0.09 (-1.43%)
12/3/2009 4:01 PM

Elan Corp, plc (ADR) (ELN)

CAPS Rating: 4 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Member Avatar bermudatrader (51.73) Submitted: 1/26/2008 4:18:14 PM : Outperform Start Price: $22.42 ELN Score: -58.62

Solid alzheimers pipeline and the best MS drug on the market.

Phase II results for AAb-001 come out this spring/summer, good data will propel this stock to the $40's.

Report this Post 0 Comments

Featured Broker Partners